Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas Lücke is active.

Publication


Featured researches published by Thomas Lücke.


Annals of Neurology | 2010

Use of guidelines improves the neurological outcome in glutaric aciduria type I

Jana Heringer; Sp Nikolas Boy; Regina Ensenauer; Birgit Assmann; Johannes Zschocke; Inga Harting; Thomas Lücke; Esther M. Maier; Chris Mühlhausen; Gisela Haege; Georg F. Hoffmann; Peter Burgard; Stefan Kölker

To evaluate the effect of treatment according to current evidence‐based recommendations on the neurological outcome of patients with glutaric aciduria type I (GA‐I).


Pediatric Research | 2007

Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by newborn screening in Germany.

Stefan Kölker; Sven F. Garbade; Nikolas Boy; Esther M. Maier; Thomas Meissner; Chris Mühlhausen; Julia B. Hennermann; Thomas Lücke; Johannes Häberle; Jochen Baumkötter; Wolfram Haller; E. Müller; Johannes Zschocke; Peter Burgard; Georg F. Hoffmann

Glutaryl-CoA dehydrogenase (GCDH) deficiency is a rare neurometabolic disorder that is considered treatable if patients are identified before the onset of acute encephalopathic crises. To allow early identification of affected individuals, tandem mass spectrometry-based newborn screening for GCDH deficiency has been started in Germany in 1999. We prospectively followed neonatally screened patients (n = 38) and compared the neurologic outcome with patients from a historical cohort (n = 62). In the majority of neonatally screened children, the onset of encephalopathic crises has been prevented (89%), whereas acute encephalopathic crises or progressive neurologic impairment was common in the historical cohort. Neonatal screening in combination with intensive management is effective – even assuming ascertainment bias in the historical cohort. Similar proportions of commonest mutations and biochemical phenotypes (high and low excretors) were found in neonatally screened and historical patients. However, potential predictor variables for mild clinical phenotypes are not yet known and thus a selection of these patients by newborn screening is not excluded. No patient was known to be missed by newborn screening from 1999 to 2005. In conclusion, this study confirms that newborn screening for GCDH deficiency in combination with intensive management is beneficial.


Clinical Chemistry and Laboratory Medicine | 2007

Developmental changes in the L-arginine/nitric oxide pathway from infancy to adulthood: plasma asymmetric dimethylarginine levels decrease with age.

Thomas Lücke; Nele Kanzelmeyer; Markus J. Kemper; Dimitrios Tsikas; Anibh M. Das

BACKGROUND The L-arginine/nitric oxide (NO) pathway has multiple physiological functions including vasodilation, inhibition of platelet aggregation and neurotransmission. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of all known NO synthase isoforms, has adverse effects on renal and cardiovascular function in adults. It is unknown whether ADMA might also exert similar effects in younger individuals including infants. Also, reference data for important members of the L-arginine/NO family, notably ADMA and the NO metabolites, nitrite and nitrate, in infancy are lacking. METHODS In the present study, we investigated the status of the L-arginine/NO pathway in 34 healthy volunteers aged 2 days to 24 years by measuring the concentration of ADMA, nitrite, nitrate and L-arginine in plasma and urine using gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry methods. RESULTS We found that ADMA levels in plasma decreased with age (Pearson correlation coefficient r=-0.619, p<0.001). In contrast, urinary excretion of nitrate (r=0.471, p=0.036) and nitrite increased with age (r=0.484, p=0.037). CONCLUSIONS Our study suggests that in infants ADMA biosynthesis accompanied by an inhibition of NO synthesis is higher than in adults and diminishes considerably with age.


Journal of Medical Genetics | 2006

Schimke immuno-osseous dysplasia: a clinicopathological correlation

J. Marietta Clewing; Barbara C. Antalfy; Thomas Lücke; Behzad Najafian; Katja M. Marwedel; Akira Hori; Ralph M. Powel; A. F Safo Do; Lydia Najera; Karen S. SantaCruz; M. John Hicks; Dawna L. Armstrong; Cornelius F. Boerkoel

Background: Schimke immuno-osseous dysplasia (SIOD) is a fatal autosomal recessive disorder caused by loss-of-function mutations in swi/snf-related matrix-associated actin-dependent regulator of chromatin, subfamily a-like 1 (SMARCAL1). Methods: Analysis of detailed autopsies to correlate clinical and pathological findings in two men severely affected with SIOD. Results: As predicted by the clinical course, T cell deficiency in peripheral lymphoid organs, defective chondrogenesis, focal segmental glomerulosclerosis, cerebral ischaemic lesions and premature atherosclerosis were identified. Clinically unexpected findings included a paucity of B cells in the peripheral lymphoid organs, emperipolesis-like (penetration of one cell by another) abnormalities in the adenohypophysis, fatty infiltration of the cardiac right ventricular wall, pulmonary emphysema, testicular hypoplasia with atrophy and azospermia, and clustering of small cerebral vessels. Conclusions: A regulatory role for the SMARCAL1 protein in the proliferation of chondrocytes, lymphocytes and spermatozoa, as well as in the development or maintenance of cardiomyocytes and in vascular homoeostasis, is suggested. Additional clinical management guidelines are recommended as this study has shown that patients with SIOD may be at risk of pulmonary hypertension, combined immunodeficiency, subcortical ischaemic dementia and cardiac dysfunction.


Journal of Child Neurology | 2013

Pediatric Herpes Simplex Virus Encephalitis A Retrospective Multicenter Experience

Lena Schleede; Wolfgang Bueter; Sara Baumgartner-Sigl; Thomas Opladen; K Weigt-Usinger; Susanne Stephan; M Smitka; Steffen Leiz; Olaf Kaiser; Verena Kraus; Andreas van Baalen; Heino Skopnik; Hans Hartmann; Kevin Rostasy; Thomas Lücke; Ulrike Schara; Martin Häusler

Knowledge on pediatric herpes simplex virus encephalitis is limited. Here we summarize 6 neonates and 32 children diagnosed by polymerase chain reaction (n = 37) or serological studies (n = 1), respectively. Diagnosis was difficult, as only 15 patients presented neurologic symptoms. Moreover, cerebrospinal fluid glucose, protein, and leukocytes were normal in 6 patients. Subsequently, all but 2 showed neurologic symptoms. Diffusion-weighted neuroimaging was the most sensitive early imaging method. Despite acyclovir treatment, 8 patients experienced early relapses, showing movement abnormalities, impaired vigilance, and seizures. Diffuse white matter changes, found in 3 of 5 relapse patients on neuroimaging, and a negative cerebrospinal fluid herpes simplex virus polymerase chain reaction suggested inflammatory processes. All relapse patients were again treated with acyclovir, and 3 responded to additional corticosteroid treatment. Whereas outcome after relapses was poor, overall outcome was good. No child died; 14 were asymptomatic at discharge, and neuroimaging remained normal in 7 of 30 patients studied.


Human Molecular Genetics | 2012

Penetrance of biallelic SMARCAL1 mutations is associated with environmental and genetic disturbances of gene expression

Alireza Baradaran-Heravi; Kyoung Sang Cho; Bas Tolhuis; Mrinmoy Sanyal; Olena Morozova; Marie Morimoto; Leah I. Elizondo; Darren Bridgewater; Joanna Lubieniecka; Kimberly Beirnes; Clara Myung; Danny Leung; Hok Khim Fam; Kunho Choi; Yan Huang; Kira Y. Dionis; Jonathan Zonana; Kory Keller; Peter Stenzel; Christy Mayfield; Thomas Lücke; Arend Bökenkamp; Marco A. Marra; Maarten van Lohuizen; David B. Lewis; Chad A. Shaw; Cornelius F Boerkoel

Biallelic mutations of the DNA annealing helicase SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1) cause Schimke immuno-osseous dysplasia (SIOD, MIM 242900), an incompletely penetrant autosomal recessive disorder. Using human, Drosophila and mouse models, we show that the proteins encoded by SMARCAL1 orthologs localize to transcriptionally active chromatin and modulate gene expression. We also show that, as found in SIOD patients, deficiency of the SMARCAL1 orthologs alone is insufficient to cause disease in fruit flies and mice, although such deficiency causes modest diffuse alterations in gene expression. Rather, disease manifests when SMARCAL1 deficiency interacts with genetic and environmental factors that further alter gene expression. We conclude that the SMARCAL1 annealing helicase buffers fluctuations in gene expression and that alterations in gene expression contribute to the penetrance of SIOD.


Annals of Neurology | 2015

Oligoclonal bands predict multiple sclerosis in children with optic neuritis

Nicole Heussinger; Evangelos Kontopantelis; Janina Gburek-Augustat; Andreas Jenke; Gesa Vollrath; Rudolf Korinthenberg; Peter Hofstetter; Sascha Meyer; Isabel Brecht; Barbara Kornek; Peter Herkenrath; Mareike Schimmel; Kirsten Wenner; Martin Häusler; Soeren Lutz; Michael Karenfort; Astrid Blaschek; M Smitka; Stephanie Karch; Martin Piepkorn; Kevin Rostasy; Thomas Lücke; Peter Weber; Regina Trollmann; Jörg Klepper; Martin Häussler; Regina Hofmann; Robert Weissert; Andreas Merkenschlager; Mathias Buttmann

We retrospectively evaluated predictors of conversion to multiple sclerosis (MS) in 357 children with isolated optic neuritis (ON) as a first demyelinating event who had a median follow‐up of 4.0 years. Multiple Cox proportional‐hazards regressions revealed abnormal cranial magnet resonance imaging (cMRI; hazard ratio [HR] = 5.94, 95% confidence interval [CI] = 3.39–10.39, p < 0.001), presence of cerebrospinal fluid immunoglobulin G oligoclonal bands (OCB; HR = 3.69, 95% CI = 2.32–5.86, p < 0.001), and age (HR = 1.08 per year of age, 95% CI = 1.02–1.13, p = 0.003) as independent predictors of conversion, whereas sex and laterality (unilateral vs bilateral) had no influence. Combined cMRI and OCB positivity indicated a 26.84‐fold higher HR for developing MS compared to double negativity (95% CI = 12.26−58.74, p < 0.001). Accordingly, cerebrospinal fluid analysis may supplement cMRI to determine the risk of MS in children with isolated ON. Ann Neurol 2015;77:1076–1082


Antimicrobial Agents and Chemotherapy | 2010

Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors.

Metodi V. Stankov; Thomas Lücke; Anibh M. Das; Reinhold Schmidt; Georg M. N. Behrens

ABSTRACT Mitochondrial dysfunction as a consequence of mitochondrial DNA (mtDNA) depletion due to therapy with nucleoside analogue reverse transcriptase inhibitors (NRTI) has been proposed as a pathogenic mechanism leading to lipoatrophy in HIV-infected patients. The aim of our study was to investigate the impact of NRTI treatment on mtDNA abundance and the activities of respiratory chain complexes in primary human subcutaneous preadipocytes (phsPA). We studied adipocyte phenotypes, viability, and differentiation (CCAAT/enhancer-binding protein α [C/EBPα] and peroxisome proliferator-activated receptor γ [PPARγ] expression) and adiponectin production, mtDNA content, mitochondrial membrane potential, mitochondrial mass, and respiratory chain enzyme and citrate synthase activities in both proliferating and differentiating phsPA. Cells were exposed to zidovudine (6 μM), stavudine (d4T; 3 μM), and zalcitabine (ddC; 0.1 μM) for 8 weeks. NRTI-induced mtDNA depletion occurred in proliferating and differentiating phsPA after exposure to therapeutic drug concentrations of d4T and ddC. At these concentrations, ddC and d4T led to an almost 50% decrease in the number of mtDNA copies per cell without major impact on adipocyte differentiation. Despite mtDNA depletion by NRTI, the activities of the respiratory chain complexes, the mitochondrial membrane potential, and the mitochondrial mass were found to be unaffected. Severe NRTI-mediated mtDNA depletion in phsPA is not inevitably associated with impaired respiratory chain activity or altered mitochondrial membrane potential.


Acta Paediatrica | 2007

Neurodevelopmental outcome and haematological course of a long-time survivor with homozygous alpha-thalassaemia: case report and review of the literature.

Thomas Lücke; Stefan Pfister; Matthias Dürken

Aim: Homozygous α‐thalassaemia, also called haemoglobin (Hb) Barts hydrops fetalis, has been thought to be a lethal condition. Due to prenatal diagnosis and intrauterine blood transfusions, a few patients with Hb Barts hydrops fetalis have survived. This fact raises the urgent questions of clinical management and appropriate follow‐up of these patients, both of which are addressed in this article. Methods: We report on a 6.5‐y‐old patient with homozygous α‐thalassaemia and review the literature of 13 other survivors published to date. Transfusion requirements were evaluated and the rate of liver iron accumulation was assessed by biomagnetic liver susceptometry before and after institution of iron‐chelating therapy. Psychometric evaluation was carried out using Munichs Functional Development Test, the Columbia Mental Maturity Scale, the Kaufman Assessment Battery for Children, and the Peabody Picture Vocabulary Test. Results: Our patient had significant delay of psychomotor development. Psychometric evaluation at the age of 5 y revealed an IQ of 85 and an intellectual level of a 4‐y‐old child. Early tissue iron overload was seen, but a negative iron balance was achieved after institution of desferrioxamine treatment at dosages used for β‐thalassaemia.


Journal of Medical Genetics | 2008

Schimke immuno-osseous dysplasia: SMARCAL1 loss-of-function and phenotypic correlation

Leah I. Elizondo; Kyoung Sang Cho; Wei Zhang; Jiong Yan; Cheng Huang; Yan Huang; Kunho Choi; Emily A. Sloan; Kimiko Deguchi; Shu Lou; Alireza Baradaran-Heravi; Hiroshi Takashima; Thomas Lücke; Florante A. Quiocho; Cornelius F. Boerkoel

Background: Schimke immuno-osseous dysplasia (SIOD) is an autosomal recessive pleiotropic disorder caused by mutations in SMARCAL1. SMARCAL1 encodes an enzyme with homology to the SNF2 chromatin remodelling proteins. Methods: To assess the affect of SMARCAL1 mutations associated with SIOD on SMARCAL1 expression and function, we characterised the effects of various mutations on mRNA and protein expression in patient tissues and cell lines, and the ATPase activity, subcellular localisation, and chromatin binding of SMARCAL1 missense mutants. Results: The SIOD associated SMARCAL1 mutations affected SMARCAL1 protein expression, stability, subcellular localisation, chromatin binding, and enzymatic activity. Further, expressing SMARCAL1 missense mutants in Drosophila melanogaster showed that disease severity was inversely proportionate to overall SMARCAL1 activity. Conclusion: Our results show for the first time that SMARCAL1 binds chromatin in vivo and that SIOD arises from impairment of diverse SMARCAL1 functions.

Collaboration


Dive into the Thomas Lücke's collaboration.

Top Co-Authors

Avatar

Anibh M. Das

Hannover Medical School

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

C. Köhler

Ruhr University Bochum

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cornelius F. Boerkoel

University of British Columbia

View shared research outputs
Researchain Logo
Decentralizing Knowledge